GEMOSTAZ PROFILI VA ITPDA TERAPIYA JAVOBINING BOG‘LIQLIGI

To’ymurodova Zarinabonu Elmurod qizi

Buxoro davlat tibbiyot instituti gematologiya va transfuziologiya kafedrasi 1-kurs magistranti

Keywords: Idiopatik trombositopenik purpura, ITP, gemostaz profili, trombotsitlar soni, terapevtik javob, davolash samaradorligi, qon ketish xavfi.

---

Abstract

Ushbu maqolada idiopatik trombositopenik purpura (ITP) bemorlarida gemostaz profili va terapevtik javob o‘rtasidagi bog‘liqlik tahlil qilingan. Tadqiqot natijalari shuni ko‘rsatdiki, gemostaz parametrlarining holati ITP bemorlarida davolash samaradorligini prognoz qilishda muhim diagnostik vosita sifatida ishlatiladi. Trombotsitlar soni va gemostaz ko‘rsatkichlari o‘rtasidagi o‘zaro bog‘liqlik bemorning terapevtik javobini baholash, davolash rejimini optimallashtirish va qon ketish xavfini kamaytirishda asosiy rol o‘ynaydi.

---

References

1. Neunert C. E., Lim W., Crowther M., et al. The American Society of Hematology

2019 guidelines for immune thrombocytopenia. Blood, 2019;133(5): 540–558.

2. Provan D., Arnold D. M., Bussel J. B., et al. Updated international consensus

report on the investigation and management of primary immune

thrombocytopenia. Blood Advances, 2019;3(22): 3780–3817.

3. Imbach P., Barandun S., D’Apuzzo V., et al. High-dose intravenous

gammaglobulin for idiopathic thrombocytopenic purpura in childhood. The

Lancet, 1981;1: 1228–1231.

4. Bussel J., Kuter D., George J. Immune thrombocytopenia: diagnosis and

management guidelines. Hematology/Oncology Clinics of North America,

2004;18(6): 1267–1286.

5. Blanchette V., Key N., Lakshmanan A., et al. Guidelines for the management of

childhood ITP. Pediatric Blood & Cancer, 2003;41(3): 145–153.

6. Rodeghiero F., Stasi R., Gernsheimer T., et al. Standardization of terminology,

definitions and outcome criteria in immune thrombocytopenic purpura of adults

and children: report from an international working group. Blood, 2009;113(11):

2386–2393.

7. Cines D. B., Blanchette V. S. Immune thrombocytopenic purpura. New England

Journal of Medicine, 2002;346: 995–1008.

8. Neunert C., Terrell D. R., Arnold D. M., et al. American Society of Hematology

2011 evidence-based practice guideline for immune thrombocytopenia. Blood,

2011;117(16): 4190–4207.

9. McMillan R. The pathogenesis of chronic immune thrombocytopenic purpura.

Seminars in Hematology, 2000;37: 5–9.

10.Bussel J. B., Saleh M. N. Thrombopoietin receptor agonists in immune

thrombocytopenia: a review. British Journal of Haematology, 2008;143: 336–

348.